Vitamin K2 and D3 work synergistically to support skeletal integrity, cardiovascular health, and optimal calcium metabolism. By delivering natural menaquinone‑7 (MK‑7) alongside cholecalciferol (D3), this supplement ensures enhanced bioavailability and targeted tissue utilization, making it an essential component of any wellness regimen.
Enhanced Bioavailability of MK‑7
Unlike phylloquinone (K1) or short‑chain menaquinones, MK‑7’s longer aliphatic side chain confers superior transport via plasma lipoproteins and a prolonged half‑life in the bloodstream. Human studies reveal that MK‑7 yields a six‑fold longer half‑life, a seven‑ to eight‑fold higher dose‑response, and a three‑fold improvement in osteocalcin carboxylation compared to K1, ensuring sustained activation of bone matrix proteins.
Synergistic Role of Vitamin D3
Cholecalciferol (D3) is the form naturally synthesized in skin upon UV exposure and plays a pivotal role in calcium absorption. Dietary and environmental factors can limit endogenous D3 production, making supplementation critical. Clinical trials demonstrate that daily D3 intake above 1,000 IU supports bone mineral density and reduces fracture risk in older adults, particularly when paired with adequate vitamin K.
Key Health Benefits
-
Bone Health: MK‑7 activates osteocalcin, the calcium‑binding protein essential for mineralization. Supplementation increases the carboxylated-to-uncarboxylated osteocalcin ratio, a direct marker of bone‑building activity.
-
Cardiovascular Support: Vitamin K2 is crucial for matrix GLA protein (MGP) carboxylation, a potent inhibitor of arterial calcification. Long‑term MK‑7 intake correlates with reduced arterial calcium deposits and improved vascular flexibility.
-
Healthy Clotting: Both K2 and D3 collaborate in the regulation of clotting factors, supporting balanced hemostasis without compromising cardiovascular safety.
Clinical Evidence & Safety
A series of human and animal studies underscore MK‑7’s efficacy at doses of 45–90 mcg/day in enhancing bone markers and lowering arterial calcification risk . MK‑7’s long half‑life enables once‑daily dosing, while D3 at 5,000–10,000 IU supports serum 25(OH)D levels without toxicity when monitored appropriately. Patients on anticoagulants should be monitored, as high K2 doses (>50 mcg/day) can affect INR values in sensitive individuals.
Pure, Allergen‑Free Formulation
Each capsule contains naturally fermented MK‑7 (Vitamk7™) and pure cholecalciferol, with minimal excipients (hypromellose, microcrystalline cellulose, silica). This clean formula excludes gluten, dairy, soy, nuts, shellfish, GMOs, artificial colors, sweeteners, and preservatives.
Advanced Research & Emerging Applications
Beyond skeletal and vascular benefits, vitamin K modulates gene expression via steroid and xenobiotic receptors, exhibits antioxidant properties, and may influence inflammatory pathways (e.g., reducing C‑reactive protein) . Ongoing research explores its role in apoptosis and cellular differentiation, hinting at broader therapeutic potential.
Integration with StrategIQ Labs’ Vision
StrategIQ Labs is dedicated to empowering long‑term wellness through doctor‑formulated, science‑backed supplements. By incorporating high‑potency MK‑7 and D3, StrategIQ Labs ensures maximal calcium utilization, vascular health, and bone resilience for its customers, aligning with its mission to support regeneration, optimization, and a smarter, longer life.
Conclusion
For those seeking a comprehensive approach to calcium metabolism and longevity, a combined Vitamin K2 and D3 supplement offers robust clinical support. With proven bioavailability, targeted tissue action, and rigorous formulation standards, it stands as a modern cornerstone in bone, heart, and metabolic health.